258 related articles for article (PubMed ID: 1363260)
1. [New anti-arrhythmia agents].
Honerjäger P; Schmidt G
Z Kardiol; 1992; 81 Suppl 4():133-7. PubMed ID: 1363260
[TBL] [Abstract][Full Text] [Related]
2. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Lazzara R
Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
[TBL] [Abstract][Full Text] [Related]
3. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
Scholz H
Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
[TBL] [Abstract][Full Text] [Related]
4. A benefit-risk assessment of class III antiarrhythmic agents.
Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
[TBL] [Abstract][Full Text] [Related]
5. [Antiarrhythmic therapy in patients with heart failure].
Faber TS; Zehender M
Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
[TBL] [Abstract][Full Text] [Related]
6. Dofetilide: a new class III antiarrhythmic agent.
Al-Dashti R; Sami M
Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
Follath F; Candinas R; Frielingsdorf J
Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
[TBL] [Abstract][Full Text] [Related]
8. Dofetilide: a new class III antiarrhythmic agent.
Roukoz H; Saliba W
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
[TBL] [Abstract][Full Text] [Related]
9. [Combination anti-arrhythmic drug therapy].
Lüderitz B; Jung W; Manz M
Z Kardiol; 1992; 81 Suppl 4():157-61. PubMed ID: 1283933
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy of ventricular arrhythmias].
Hohnloser SH
Med Klin (Munich); 1997 Apr; 92(4):208-10. PubMed ID: 9221302
[TBL] [Abstract][Full Text] [Related]
11. Class III antiarrhythmic drugs.
Singh BN; Ahmed R
Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
[TBL] [Abstract][Full Text] [Related]
12. Potentially significant drug interactions of class III antiarrhythmic drugs.
Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
[TBL] [Abstract][Full Text] [Related]
14. Pure class III agents for prevention of sudden cardiac death.
Pratt CM
J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study].
Meinertz T; Zehender M; Hohnloser SH
Z Kardiol; 1992; 81 Suppl 4():145-9. PubMed ID: 1290291
[TBL] [Abstract][Full Text] [Related]
16. A benefit-risk assessment of class III antiarrhythmic agents.
Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
[TBL] [Abstract][Full Text] [Related]
17. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
Singh BN
Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
[TBL] [Abstract][Full Text] [Related]
18. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
Tsikouris JP; Cox CD
Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of sotalol for life-threatening ventricular arrhythmias.
Roden DM
Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727
[TBL] [Abstract][Full Text] [Related]
20. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
